These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21277938)

  • 1. Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer.
    Di Marcotullio L; Canettieri G; Infante P; Greco A; Gulino A
    Biochim Biophys Acta; 2011 Apr; 1815(2):241-52. PubMed ID: 21277938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of HDACs in normal and malignant hematopoiesis.
    Wang P; Wang Z; Liu J
    Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma.
    De Smaele E; Di Marcotullio L; Moretti M; Pelloni M; Occhione MA; Infante P; Cucchi D; Greco A; Pietrosanti L; Todorovic J; Coni S; Canettieri G; Ferretti E; Bei R; Maroder M; Screpanti I; Gulino A
    Neoplasia; 2011 Apr; 13(4):374-85. PubMed ID: 21472142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging HDAC inhibitors for cancer treatment.
    West AC; Johnstone RW
    J Clin Invest; 2014 Jan; 124(1):30-9. PubMed ID: 24382387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
    Petta V; Gkiozos I; Strimpakos A; Syrigos K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.
    Marks PA
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1049-66. PubMed ID: 20687783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Agents-Mediated Targeting of Histone Deacetylases.
    Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of HDACs--effective drugs against cancer?
    Müller S; Krämer OH
    Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma.
    Yang Q; Falahati A; Khosh A; Mohammed H; Kang W; Corachán A; Bariani MV; Boyer TG; Al-Hendy A
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of histone deacetylases in cancer.
    Montezuma D; Henrique RM; Jerónimo C
    Crit Rev Oncog; 2015; 20(1-2):19-34. PubMed ID: 25746102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of HDAC in cancer: the nuclear and epigenetic components.
    Hagelkruys A; Sawicka A; Rennmayr M; Seiser C
    Handb Exp Pharmacol; 2011; 206():13-37. PubMed ID: 21879444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of histone deacetylases (HDACs) in human cancer.
    Ropero S; Esteller M
    Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.